Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019552 · ClinicalTrials.gov registry record · Phase 2
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019552: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019552 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019552, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.
Interventions
- DRUG irofulven
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00019552 record still lists
NCT00019552 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which irofulven is the first listed.
NCT00019552 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019552 about?
NCT00019552 is a clinical study titled "Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.
What is the current status of trial NCT00019552?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-09. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00019552?
The interventions under investigation include: irofulven (DRUG).
Who is sponsoring clinical trial NCT00019552?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia